Work

A Case to Support the Continued Use of Rifampin in Clinical Drug–Drug Interaction Studies

Year: 2024

Type: article

Source: Clinical Pharmacology & Therapeutics

DOI: 10.1002/cpt.3256

Authors: Joel P. Bercu, David J. Ponting, Sharon L. Ripp, Krista L. Dobo, Rheem A. Totah, Jayaprakasam Bolleddula

Institutions: Gilead Sciences (United States), Pfizer (United States), University of Washington, Merck Healthcare KGaA, Darmstadt (Germany)

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4392920091

FWCI: 1.666

Cites: 8

Cited by: 4

Related to: 10